高危横纹肌肉瘤患者维持化疗:欧洲儿童软组织肉瘤研究组RMS 2005试验长期生存分析
欧洲儿童软组织肉瘤研究组RMS 2005试验评估高危横纹肌肉瘤维持化疗,患者随机分为停药组(标准组)或接受6个28天周期长春瑞滨(25 mg/m2,第1、8、15天每日一次)联合每日一次低剂量环磷酰胺(25 mg/m2)组(试验组)。中位随访122.1个月后,10年无病生存率标准组66.5% vs 试验组77.1%(P = .025),10年总生存率标准组70.8% vs 试验组82.9%(P = .0099)。长期结果证实长春瑞滨联合低剂量环磷酰胺维持化疗的生存获益。
要点
- 高危横纹肌肉瘤患者随机接受维持化疗或停药,中位随访122.1个月。
- 10年无病生存率标准组66.5% vs 试验组77.1%(P = .025)。
- 10年总生存率标准组70.8% vs 试验组82.9%(P = .0099)。
核心结论
- RMS2005试验长期结果证实,长春瑞滨联合低剂量环磷酰胺维持化疗对高危横纹肌肉瘤患者具有生存获益。
研究设计与样本
- 欧洲儿童软组织肉瘤研究组(EpSSG)RMS 2005随机试验,2006年4月至2016年12月入组,标准组186例,试验组185例。
主要发现
- 中位随访自诊断起122.1个月、自随机分组起114个月,103例患者发生复发、进展或死亡(标准组61例,试验组42例)。
- 10年无病生存率标准组66.5%(95% CI,59至74)vs 试验组77.1%(95% CI,70.3至82.5),P = .025。
- 10年总生存率标准组70.8%(95% CI,63.3至77.0)vs 试验组82.9%(95% CI,76.6至87.7),P = .0099。
关键数值与推荐
- 标准组为停药,试验组接受6个28天周期长春瑞滨(25 mg/m2)每日一次于第1、8、15天,联合每日一次低剂量环磷酰胺(25 mg/m2)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 trial evaluated maintenance chemotherapy in high-risk rhabdomyosarcoma (RMS). Patients were randomly assigned to either discontinue treatment (standard arm) or receive six 28-day cycles of vinorelbine (25 mg/m2) once per day on days 1, 8, and 15, plus once daily low-dose cyclophosphamide (25 mg/m2; experimental arm). Initial results showed improved overall survival (OS), but disease-free survival (DFS) improvement was not statistically significant. This report presents mature survival outcomes after extended follow-up. Between April 2006 and December 2016, 186 patients were enrolled in the standard arm and 185 in the experimental arm. After a median follow-up of 122.1 months from diagnosis and 114 months from random assignment, recurrence, progression, or death occurred in 103 patients (61 standard arm, 42 experimental arm). The 10-year DFS was 66.5% (95% CI, 59 to 74) in the standard arm versus 77.1% (95% CI, 70.3 to 82.5) in the experimental arm (P = .025). Corresponding 10-year OS rates were 70.8% (95% CI, 63.3 to 77.0) and 82.9% (95% CI, 76.6 to 87.7; P = .0099). Long-term results of the RMS2005 trial confirm the survival benefit of maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide for patients with high-risk RMS.
引用
- Bisogno G, Chisholm J, Hladun R, et al. Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European Paediatric Soft Tissue Sarcoma Study Group RMS 2005 Trial. J Clin Oncol. 2025. PMID: 40053891. doi:10.1200/JCO-24-02850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。